Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Heron Therapeutics (HRTX) EBIAT (2016 - 2026)

Heron Therapeutics filings provide 15 years of EBIAT readings, the most recent being -$8.1 million for Q1 2026.

  • On a quarterly basis, EBIAT fell 407.82% to -$8.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$30.9 million, a 297.44% decrease, with the full-year FY2025 number at -$20.2 million, down 48.71% from a year prior.
  • EBIAT hit -$8.1 million in Q1 2026 for Heron Therapeutics, down from -$3.0 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $3.7 million in Q4 2024 to a low of -$63.9 million in Q1 2022.
  • Median EBIAT over the past 5 years was -$10.7 million (2023), compared with a mean of -$19.7 million.
  • Biggest five-year swings in EBIAT: soared 183.39% in 2025 and later crashed 407.82% in 2026.
  • Heron Therapeutics' EBIAT stood at -$19.9 million in 2022, then soared by 46.03% to -$10.7 million in 2023, then surged by 134.16% to $3.7 million in 2024, then plummeted by 180.64% to -$3.0 million in 2025, then tumbled by 174.58% to -$8.1 million in 2026.
  • The last three reported values for EBIAT were -$8.1 million (Q1 2026), -$3.0 million (Q4 2025), and -$17.5 million (Q3 2025) per Business Quant data.